Transcatheter aortic valve implantation in Asia: the first decade
- Eurointervention 2018; 14: 35-37.
Last year, the interventional cardiology community commemorated the 15th anniversary of the birth of transcatheter aortic valve implantation (TAVI)1. Since European commercial approval was granted in 2007, the expansion and uptake of TAVI in Europe has been phenomenal2.
In comparison, TAVI only reached the shores of Asia two years later, when the procedure was first performed in Singapore in February 2009, using the SAPIEN valve (Edwards Lifesciences, Irvine, CA, USA)3. Subsequently, CoreValve® (Medtronic, Minneapolis, MN, USA) was launched commercially in Malaysia in October 2009.…